Researchers Validate miRNA Dx as Tool to Discern if High-risk Lung Cancer Patients Should Get LDCT | GenomeWeb

NEW YORK (GenomeWeb) – A group of Italian researchers have validated a microRNA-based blood test for early detection of lung cancer that they hope to introduce as a first-line tool that doctors can use to select which patients should go on to receive additional screening with low-dose computed tomography (LDCT).

The so-called miR-Test analyzes patients' serum based on a 13-miRNA signature and deems them either positive or negative for lung cancer. miRNAs are frequently abnormally expressed in tumors, and this irregularity shows up in miRNA profiles in serum and plasma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.